Even if CNS-penetrant BTKi treatment indeed proves effective at limiting progressive MS, establishing that such an outcome is mediated through BTKi effects on CNS B cells will not be straightforward, since BTK is also expressed by infiltrating macrophage and resident tissue microglia. This evidence concerns the gene IBTK and myeloid sarcoma.